close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

3.980 -0.030 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B ↗
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate ↗
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress... 
Via Benzinga
Why Arbutus Biopharma's Stock Is Trading Lower Today ↗
Arbutus Biopharma's Stock Price And Volume Action Arbutus Biopharma's (NASDAQ: 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
24 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
News headline image
24 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Senseonics Holdings, Inc. (NYSE: SENS) rose 37.1% to $2.81 in pre-market trading after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
News headline image
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech ↗
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
28 Stocks Moving in Friday's Pre-Market Session ↗
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares rose 28.5% to $0.7451 in pre-market trading after the company reported better-than-expected Q1 sales. Bionano Genomics, Inc. (NASDAQ:... 
Via Benzinga
News headline image
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines ↗
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs. Here is a look back at the week in SPACs for... 
Via Benzinga
News headline image
Arbutus Biopharma (ABUS) Q1 2021 Earnings Call Transcript ↗
ABUS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company ↗
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning. The SPAC Deal:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today